589 related articles for article (PubMed ID: 31506387)
1. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
[TBL] [Abstract][Full Text] [Related]
2. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F; Jao K; Greillier L; Cho BC; Penkov K; Reguart N; Majem M; Nackaerts K; Syrigos K; Hansen K; Schuette W; Cetnar J; Cappuzzo F; Okamoto I; Erman M; Langer SW; Kato T; Groen H; Sun Z; Luo Y; Tanwani P; Caffrey L; Komarnitsky P; Reinmuth N
J Thorac Oncol; 2021 Sep; 16(9):1547-1558. PubMed ID: 33607312
[TBL] [Abstract][Full Text] [Related]
4. Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
Udagawa H; Akamatsu H; Tanaka K; Takeda M; Kanda S; Kirita K; Teraoka S; Nakagawa K; Fujiwara Y; Yasuda I; Okubo S; Shintani M; Kosloski MP; Scripture C; Tamura T; Okamoto I
Lung Cancer; 2019 Sep; 135():145-150. PubMed ID: 31446987
[TBL] [Abstract][Full Text] [Related]
5. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.
Johnson ML; Zvirbule Z; Laktionov K; Helland A; Cho BC; Gutierrez V; Colinet B; Lena H; Wolf M; Gottfried M; Okamoto I; van der Leest C; Rich P; Hung JY; Appenzeller C; Sun Z; Maag D; Luo Y; Nickner C; Vajikova A; Komarnitsky P; Bar J
J Thorac Oncol; 2021 Sep; 16(9):1570-1581. PubMed ID: 33823285
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
[TBL] [Abstract][Full Text] [Related]
7. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
Calvo E; Spira A; Miguel M; Kondo S; Gazzah A; Millward M; Prenen H; Rottey S; Warburton L; Alanko T; Cassier PA; Yoh K; Italiano A; Moreno V; Peltola K; Seto T; Toyozawa R; Afar DE; Englert S; Komarnitsky P; Lambert S; Parikh A; Vosganian G; Gao B
Cancer Treat Res Commun; 2021; 28():100405. PubMed ID: 34329846
[TBL] [Abstract][Full Text] [Related]
9. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
[TBL] [Abstract][Full Text] [Related]
10. A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.
Hann CL; Burns TF; Dowlati A; Morgensztern D; Ward PJ; Koch MM; Chen C; Ludwig C; Patel M; Nimeiri H; Komarnitsky P; Camidge DR
J Thorac Oncol; 2021 Sep; 16(9):1582-1588. PubMed ID: 34242790
[TBL] [Abstract][Full Text] [Related]
11. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
[TBL] [Abstract][Full Text] [Related]
12. Rovalpituzumab tesirine resistance: analysis of a corresponding small cell lung cancer and circulating tumor cell line pair.
Rath B; Plangger A; Krenbek D; Hochmair M; Stickler S; Tretter V; Hamilton G
Anticancer Drugs; 2022 Mar; 33(3):300-307. PubMed ID: 34924498
[TBL] [Abstract][Full Text] [Related]
13. DLL3: an emerging target in small cell lung cancer.
Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.
Malhotra J; Nikolinakos P; Leal T; Lehman J; Morgensztern D; Patel JD; Wrangle JM; Curigliano G; Greillier L; Johnson ML; Ready N; Robinet G; Lally S; Maag D; Valenzuela R; Blot V; Besse B
J Thorac Oncol; 2021 Sep; 16(9):1559-1569. PubMed ID: 33652156
[TBL] [Abstract][Full Text] [Related]
16. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.
Spino M; Kurz SC; Chiriboga L; Serrano J; Zeck B; Sen N; Patel S; Shen G; Vasudevaraja V; Tsirigos A; Suryadevara CM; Frenster JD; Tateishi K; Wakimoto H; Jain R; Riina HA; Nicolaides TP; Sulman EP; Cahill DP; Golfinos JG; Isse K; Saunders LR; Zagzag D; Placantonakis DG; Snuderl M; Chi AS
Clin Cancer Res; 2019 Feb; 25(4):1261-1271. PubMed ID: 30397180
[TBL] [Abstract][Full Text] [Related]
17. Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate.
Lashari BH; Vallatharasu Y; Kolandra L; Hamid M; Uprety D
Drugs R D; 2018 Dec; 18(4):255-258. PubMed ID: 30232719
[TBL] [Abstract][Full Text] [Related]
18. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
[TBL] [Abstract][Full Text] [Related]
19. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
[No Abstract] [Full Text] [Related]
20. Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.
Chiang AC; Sequist LVD; Gilbert J; Conkling P; Thompson D; Marcoux JP; Gettinger S; Kowanetz M; Molinero L; O'Hear C; Fassò M; Lam S; Gordon MS
Clin Lung Cancer; 2020 Sep; 21(5):455-463.e4. PubMed ID: 32586767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
